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Abstract
Background: The effect of dietary fats on human health and disease are likely mediated by changes in gene expression.
Several transcription factors have been shown to respond to fatty acids, including SREBP-1c, NF-kB, RXRs, LXRs, FXR, HNF4a,
and PPARs. However, it is unclear to what extent these transcription factors play a role in gene regulation by dietary fatty
acids in vivo.
Methodology/Principal Findings: Here, we take advantage of a unique experimental design using synthetic triglycerides
composed of one single fatty acid in combination with gene expression profiling to examine the effects of various individual
dietary fatty acids on hepatic gene expression in mice. We observed that the number of significantly changed genes and the
fold-induction of genes increased with increasing fatty acid chain length and degree of unsaturation. Importantly, almost
every single gene regulated by dietary unsaturated fatty acids remained unaltered in mice lacking PPARa. In addition, the
majority of genes regulated by unsaturated fatty acids, especially docosahexaenoic acid, were also regulated by the specific
PPARa agonist WY14643. Excellent agreement was found between the effects of unsaturated fatty acids on mouse liver
versus cultured rat hepatoma cells. Interestingly, using Nuclear Receptor PamChipH Arrays, fatty acid- and WY14643-
induced interactions between PPARa and coregulators were found to be highly similar, although several PPARa-coactivator
interactions specific for WY14643 were identified.
Conclusions/Significance: We conclude that the effects of dietary unsaturated fatty acids on hepatic gene expression are
almost entirely mediated by PPARa and mimic those of synthetic PPARa agonists in terms of regulation of target genes and
molecular mechanism. Use of synthetic dietary triglycerides may provide a novel paradigm for nutrigenomics research.
Citation: Sanderson LM, de Groot PJ, Hooiveld GJEJ, Koppen A, Kalkhoven E, et al (2008) Effect of Synthetic Dietary Triglycerides: A Novel Research Paradigm for
Nutrigenomics. PLoS ONE 3(2): e1681. doi:10.1371/journal.pone.0001681
Editor: Simon Williams, Texas Tech University Health Sciences Center, United States of America
Received December 6, 2007; Accepted January 24, 2008; Published February 27, 2008
Copyright:  2008 Sanderson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
*E-mail: sander.kersten@wur.nl
Introduction
Dietary fatty acids have multiple functions in the human body.
They are an important energy source, form an essential part of the
phospholipid bilayer of membranes, and function as precursors to
several signaling molecules, such as the eicosanoids. A huge body
of literature collected in the past few decades provides compelling
evidence that changes in the dietary fatty acid composition can
profoundly influence health and disease. For example, it is well
established that replacing dietary saturated fatty acids with n-6
mono- and polyunsaturated leads to a decrease in plasma
concentration of low density lipoprotein, which is a well-known
risk factor for atherosclerosis [1]. Likewise, increased consumption
of n-3 fatty acids, especially eicosapentaenoic acid and docosahex-
aenoic acid present in fish oil, is associated with decreased plasma
triglyceride concentrations [2], may prevent against cardiac
arrhythmias [3], and improves visual acuity in preterm infants
[4]. Numerous molecular mechanisms may underlie the effects of
dietary fatty acids on parameters of health. While historically the
main focus was on changes in plasma membrane fluidity as a result
of changes in phospholipid composition, the discovery of nuclear
receptors has progressively shifted the emphasis to regulation of
gene expression.
The superfamily of nuclear receptors encompasses a related but
diverse set of transcription factors that share a number of
structural and functional features [5]. They consist of a central
DNA-binding domain that directs the receptor to specific DNA
sequences within a gene promoter, and a ligand-binding domain,
which can accommodate a variety of different compounds.
Roughly, nuclear receptors can be divided into three main groups:
the endocrine receptors that bind steroid hormones, the adopted
orphan receptors that bind dietary lipids, and the orphan
receptors, for which no ligand exists or still has to be identified
[6]. The adopted orphan receptors share a common mode of
action that involves heterodimerization with the nuclear Retinoid
X Receptor (RXR). Binding of ligands to the receptor leads to
recruitment of co-activators and dissociation of co-repressors,
resulting in chromatin remodeling followed by initiation of DNA
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transcription. Adopted orphan receptors mainly function as lipid
sensors by altering the rate of transcription of specific genes in
response to changes in lipid concentration [6]. These lipids include
oxysterols, bile acids, and fat soluble vitamins. In addition, many
adopted orphan receptors have been shown to bind fatty acids and
alter transcription in response to changes in fatty acid concentration
and/or composition, including RXR, Peroxisome-Proliferator
Activated Receptors (PPARa, b/d and c), Hepatic Nuclear Factor
4a (HNF-4a), Liver X Receptor (LXR) a and b, and Farnesoid X
Receptor [7,8]. Other receptors that mediate the effects of dietary
fatty acids on gene expression include the Sterol Regulatory Element
Binding Protein 1, and the Nuclear factor kappaB [7]. However, the
relative contribution of all these receptors to fatty acid-dependent
gene regulation in vivo remains completely unclear.
Here, we take advantage of a unique experimental design using
synthetic triglycerides composed of one single fatty acid in
combination with gene expression profiling to examine the effects
of individual dietary fatty acids on hepatic gene expression in mice.
By conducting these experiments in wild-type and PPARa 2/2
mice, we were able to explore the specific contribution of PPARa.
We conclude that the effects of dietary unsaturated fatty acids on
hepatic gene expression are almost exclusively mediated by
PPARa and mimic those of synthetic PPARa agonists in terms
of target genes regulation and molecular mechanism.
Results
Mice that were fasted for 4 hours were given a single oral dose
(400 ml) of synthetic triglycerides (TGs) consisting of one single fatty
acid, followed by collection of tissues 6 hours thereafter (Figure 1). A
parallel treatment in mice lacking PPARa was performed to enable
estimation of the importance of PPARa in gene regulation by dietary
fatty acids. The fatty acids studied were oleic acid (C18:1), linoleic
acid (C18:2), linolenic acid (C18:3), eicosapentaenoic acid (C20:5),
and docosahexaenoic acid (C22:6). No saturated fatty acids were
included because triglycerides composed of common dietary
saturated fatty acids are solid at room temperature and could not
be administered orally. The 6-hour time point was chosen because in
an independent oral fat load experiment, plasma triglyceride (TG)
levels peaked 2 hours after the fat load and almost returned back to
baseline after 6 hours (Figure S1A), indicating that at that point most
of the fat bolus has been cleared from the blood and taken up by the
tissues. Indeed, we observed that 6 hours after oral dosing plasma
TG levels had almost returned to baseline (Figure S1B), and were
similar in WT and PPARa 2/2 mice, suggesting no major
differences in plasma TG kinetics between the various fatty acids and
between WT and PPARa 2/2. Also, no major differences in the
rate of intestinal TG absorption were observed between WT and
PPARa2/2mice (Figure S1C). Finally, while as expected liver TG
levels were higher in the PPARa2/2mice compared to WTmice,
in the WT mice liver TG levels were similar between the various
fatty acids (Figure S1D). These data argue against major differences
in metabolic processing of dietary fat between WT and PPARa
2/2 mice and between different dietary fatty acids.
The focus of the present study is on liver since we observed that,
when expressed per gram organ weight, the liver and heart take up
most of the fatty acids present in TG-rich lipoproteins (Figure
S1E). A future publication will address the effect of dietary fatty
acids on gene expression and the involvement of PPARs in heart.
PPARa-dependent gene regulation by dietary
unsaturated fatty acids
Expression profiling was carried out on individual mouse livers.
Use of Affymetrix Mouse Genome 430 2.0 Arrays (whole mouse
genome array), which contain more than 45000 probesets
corresponding to over 34000 genes, allows for a genome-wide
analysis of the number of significantly changed genes in the
various treatment groups. After inter-quartile range (IQR)
filtering, 11463 probesets (equivalent to 7231 genes) were left for
analysis. A regularized t-test was performed to analyze changes in
gene expression between the control and oral triglyceride group.
The regularized t-test statistic has the same interpretation as an
ordinary t-test statistic, except that the standard errors have been
moderated across genes, i.e. shrunk to a common value, using a
Bayesian model [9]. A probeset was found to be significantly
changed after treatment if P,0.01. All microarray results have
been deposited into the Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/projects/geo/) and can be accessed online
under series number GSE8396. Quantitative real-time PCR was
carried out on ,30 genes in order to confirm the results from the
microarray, and the results were found to be in close agreement
with the microarray data (Figure S2).
The highest number of statistically significantly changed genes
was found after treatment with C22:6 (519, P,0.01), followed by,
in turn, C18:3 (400), C18:2 (287), C20:5 (280) and C18:1 (114)
(Figure 2 and table S1). These numbers are relatively low in
comparison with the synthetic PPARa agonists WY14643 (1674)
Figure 1. Schematic representation of dietary intervention. Wild-type and PPARa 2/2 mice fasted for 4 hours were given a single oral dose
of different synthetic triglycerides composed of one single unsaturated fatty acid (400 ml), or one of the PPARa agonists WY14643 or fenofibrate
(4 mg). After 6h, the livers were used for gene expression profiling using Affymetrix Mouse Genome 430 2.0 Microarrays (,45000 probesets) on
biological replicates. CMC= carboxymethyl cellulose.
doi:10.1371/journal.pone.0001681.g001
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and fenofibrate (1005). The data indicate that of all fatty acids
studied, C22:6 is the most potent activator of gene expression.
Regulation of gene expression by dietary fatty acids or synthetic
agonists was defined as PPARa-dependent when expression was
statistically significantly up- or downregulated in WT but not
PPARa 2/2 mice. As expected, gene regulation by WY14643
and fenofibrate in WT mice was almost completely abolished in
PPARa 2/2 mice. Surprisingly, a similar though slightly less
extreme picture was observed for dietary unsaturated fatty acids.
Indeed, the far majority of genes regulated by dietary unsaturated
fatty acids in WT mice did not show regulation in PPARa 2/2
mice, indicating PPARa-dependent regulation. This was highest
for C20:5 (94.6%), followed by C22:6 (93.1%), C18:1 (88.6%),
C18:2 (87.1%) and C18:3 (84.0%) (Figure 2 and table S1). Similar
numbers were obtained for up- and downregulation of gene
expression. The few genes that were up- or downregulated by
dietary unsaturated fatty acids independently of PPARa included
Lpin2 and Srebp-1, respectively. Together, these data suggest that
the (short term) effects of dietary unsaturated fatty acids on hepatic
gene expression are almost exclusively mediated by PPARa.
Overlap in gene regulation between dietary unsaturated
fatty acids and WY14643
To further explore the role of PPARa in regulation of gene
expression by dietary unsaturated fatty acids, the overlap in gene
regulation between fatty acids and WY14643, which specifically
targets PPARa, was studied. Remarkably, C22:6 showed a huge
overlap in gene regulation with WY14643 (Figure 3A). Quanti-
tatively, 84% of genes upregulated and 76% of genes downreg-
ulated by C22:6 (P,0.01) were also regulated by WY14643
(average 80.5%), suggesting that C22:6 impacts mainly PPARa
target genes. Much less overlap was observed between C18:1 and
WY14643 (average 32.4%), suggesting that gene regulation by
C18:1 may be less dependent on PPARa, or alternatively the
existence of PPARa target genes specifically regulated by C18:1
(Figure 3A). An intermediate degree of overlap was observed
between WY14643 and the other fatty acids studied (Table S2).
To further compare the effects of WY14643 and C22:6 on gene
expression, for all probesets left after IQR-filtering the fold-changes
in expression in response to WY14643 and C22:6 were plotted
against each other, with each probeset represented by a single dot
(Figure 3B). The vast majority of probesets ended up in the lower left
or upper right compartments, indicating that genes up- or
downregulated by WY14643 were also up- or downregulated by
C22:6, respectively, thus confirming the overlap in gene regulation
between C22:6 and WY14643. Additionally, the positioning of the
dots around a straight line with slope ,1 shows that the relative
magnitude of gene induction by C22:6 related to WY14643 was
remarkably constant across all probesets. Thus, compared to
WY14643, C22:6 behaves as an almost equally specific, yet less
potent PPARa agonist. Nevertheless, several genes could be
identified that were upregulated disproportionally strongly by
WY14643 including Cd36, Fabp4 (aP2), and Cpt1b, or by C22:6
including Prlr and Txnip (Figure 3B). A much more scattered picture
was observed for the comparison between WY14643 and C18:1,
indicating that these compounds have much less in common in terms
of gene regulation. Again, the other fatty acids gave an intermediate
picture (data not shown).
An alternative approach to study similarities in gene regulation is
via determining the overlap in Gene Ontology (GO) classes
overrepresented in the respective treatment groups (Table S3). P-
values derived from t-test for all,45000 probesets on the microarray
were used for the GO-based functional clustering. The comparisons
were made between the control group and each treatment group in
wild-type mice. Out of a total of 19 GO classes overrepresented after
C22:6 treatment, only one class (GO:0016070, RNA metabolism)
was not shared between C22:6 and WY14643 (Figure 3C).
Interestingly, this GO class was shared between C22:6 and C18:1
suggesting it may be specifically regulated by dietary unsaturated
fatty acids and not WY14643. The remainder of fatty acids studied,
except for perhaps C18:1, similarly showed a high degree of overlap
with WY14643 (Table S4), thereby corroborating the very large
resemblance in gene regulation between WY14643 and the dietary
fatty acids studied. Overall, these data support the dominant role of
PPARa in gene regulation by dietary unsaturated fat.
Figure 2. PPARa-dependent regulation of gene expression by dietary unsaturated fatty acids. Bars show number of up- (upper panel)
and downregulated (lower panel) probesets in the different treatment groups. The number of probesets regulated by unsaturated fatty acids in a
PPARa-dependent manner (light bars, not changed in the PPARa 2/2 mouse), or PPARa-independent manner (dark bars, changed in wild-type and
PPARa2/2mice) are shown, with percentage PPARa dependence indicated. Probesets were considered statistically significantly regulated if P,0.01.
doi:10.1371/journal.pone.0001681.g002
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Hierarchy between dietary unsaturated fatty acids
Of all fatty acids studied, the number of significantly changed
genes was highest for C22:6, followed by C18:3. The number was
about equal for C20:5 and C18:2, while much fewer genes were
changed after C18:1 treatment. Since the dietary fatty acids
regulated gene expression principally via PPARa, the data are
indicative of a hierarchy in in vivo PPARa-activating potency
between dietary unsaturated fatty acids. Direct evidence for this
notion came from comparison of fold-changes in expression of
PPARa target genes between the various fatty acid treatments.
Genes involved in two major PPARa-regulated pathways were
examined: mitochondrial fatty acid oxidation and peroxisomal
fatty acid oxidation (Figure 4). These functional classes were
created in house for various pathways within lipid metabolism and
were specifically designed for Affymetrix GeneChip analysis
(available at http://nutrigene.4t.com/microarray/ppar2007). By
visualizing the changes in gene expression in the form of a
heatmap, a clear hierarchy in PPARa-activating potency can be
observed between the various treatments, which can be expressed
as WY.feno.22:6.20:5 = 18:3.18:2.18:1.
Since a direct comparison between synthetic agonists and
dietary fatty acids is complicated by differences in dosage (4 mg vs.
400 ml), further comparisons were made between fatty acids only.
For all probesets shown in the heatmaps as well as probesets
belonging to the lipogenesis pathway we estimated the relative
induction by each fatty acid expressed as a percentage of induction
Figure 3. Similarities between two dietary unsaturated fatty acids and the synthetic PPARa agonist WY14643. (A) Venn diagrams
showing the overlap in up- (left panel) and downregulated (right panel) genes after treatment with WY14643, C22:6 and C18:1. Genes were
considered statistically significantly regulated if P,0.01. (B) Scatter plots demonstrating similarities in gene regulation between C22:6 and WY14643.
Graphs show fold change in gene expression after treatment with WY14643 compared to C22:6 and C18:1. Genes that are upregulated
disproportionally strongly by WY14643 (Cd36, Fabp4 (aP2), and Cpt1b), or by C22:6 (Prlr and Txnip) are marked. In constructing the scatter plots, all
probesets left after IQR-filtering were used. (C) Overlap in overrepresented Gene Ontology classes between C22:6, C18:1, and WY14643, based on a
functional class score (FCS) method. The GO class unique to C22:6 and C18:1 is GO:0016070 (RNA metabolism), whereas the GO classes unique to
C18:1 are GO:0007409 (axonogenesis) and GO:0016072 (rRNA metabolism).
doi:10.1371/journal.pone.0001681.g003
Gene Regulation by Dietary Fat
PLoS ONE | www.plosone.org 4 February 2008 | Volume 3 | Issue 2 | e1681
by C22:6. The median for all probesets within a functional class
was calculated for each treatment group (Figure S3, bar). These
data indicate that C22:6 is the most potent activator of PPARa-
dependent gene regulation in mouse liver, while C18:1 is the least
active.
To examine whether the difference in in vivo PPARa-activating
potency between the dietary fatty acids could be reproduced in
vitro, cultured rat FAO hepatoma cells were treated with various
unsaturated fatty acids. It was observed that the pattern of
regulation of PPARa targets Pdk4, Ehhadh and Cyp4A14 by
unsaturated fatty acids was highly similar between the FAO cells
and intact mouse liver (Figure 5). These data provide additional
evidence that differences in metabolic processing of fatty acids are
unlikely to explain differential fold-induction of genes between
dietary fatty acids observed in vivo. Rather, they indicate an
intrinsic difference in PPARa-activating potency between dietary
unsaturated fatty acids, which is supported by published in vitro
data.
While in terms of target gene regulation dietary unsaturated
fatty acids thus generally mimic the effect of the synthetic PPARa
agonist WY14643 except for being less potent, it is unclear
whether these different compounds activate PPARa and stimulate
Figure 4. Differential induction of genes involved in fatty acid oxidation between various dietary fatty acids. (A) Genes involved in
mitochondrial fatty acid oxidation. (B) Genes involved in peroxisomal fatty acid oxidation. The heatmaps were generated directly from the microarray
data, using for each probeset the mean signal from 4–5 biological replicates. The grayscale represents fold-induction relative to wild-type control,
which was set at 1. Only probesets showing significant (P,0.01) upregulation by WY14643 were included in the analysis. A list of probesets
belonging to the functional class of mitochondrial fatty acid oxidation can be found at http://nutrigene.4t.com/microarray/ppar2007.
doi:10.1371/journal.pone.0001681.g004
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transcription of target genes via the exact same mechanism. To
explore this issue we used Nuclear Receptor PamChipH Arrays to
identify differences in coregulator recruitment between WY14643
and C22:6. In this system the interaction between nuclear
receptors and immobilized peptides corresponding to specific
coregulator-nuclear receptor binding regions is studied. Both
C22:6 and WY14643 promoted the interaction between PPARa
and numerous coregulator peptides. Interestingly, no PPARa-
coregulator interactions unique to C22:6 could be identified.
However, at least 4 interactions, representing the coregulator
proteins TRIP3, TRIP8, RIP140, and the nuclear receptor SHP1,
seemed to be elicited specifically by WY14643 (Figure 6). No
differences in PPARa-coregulator interaction patterns could be
observed between the various fatty acids studied (data not shown).
Discussion
Dietary fats have numerous effects on human health. Current
dietary guidelines strongly discourage consumption of saturated
and trans fatty acids, whereas consumption of unsaturated fatty
acids, especially n-3 fatty acids present in fish oil, is promoted [10–
12]. It is believed that dietary fatty acids mainly influence
biological processes by altering DNA transcription. In the present
paper, using a unique dietary intervention protocol consisting of a
single dose of synthetic triglycerides composed of a single fatty
acid, we show that in mouse liver PPARa dominates gene
regulation by dietary unsaturated fat. Furthermore, we demon-
strate that dietary PUFAs, especially docosahexaenoic acid, are the
most potent activators of PPARa in vivo. These latter data align
well with in vitro experiments showing that in general PUFAs are
more potent PPARa ligands compared to mono- and saturated
fatty acids, although the results may depend somewhat on the
method used [13–19].
It can be argued that our data and conclusions may be biased
due to possible differential absorption and metabolic processing
between the various fatty acids and between WT and PPARa 2/
2 mice. Unfortunately, the unavailability of radioactive TG
besides triolein makes it impossible to get complete and
comparative information on the kinetic behavior of the various
fatty acids used. However, several lines of evidence argue against
major differences in kinetic behavior between the fatty acids: 1) it
has been previously demonstrated that hepatic uptake of fatty
acids from chylomicron remnants is unaffected by the fatty acid
composition. [20]; 2) at the moment of sacrifice, plasma TG levels
were highly similar for the various fatty acid groups; 3) fatty acid
treatment in vivo and in vitro revealed a similar hierarchy in PPARa-
activating potency between the fatty acids and in both analyses
C22:6 emerged as the most potent PPARa agonist.
In addition, no major differences in the kinetics of dietary fat
metabolism are expected between WT and PPARa 2/2 mice as:
1) WT and PPARa 2/2 mice show similar rates of intestinal TG
absorption; 2) at the moment of sacrifice, plasma TG levels were
highly similar between WT and PPARa 2/2 mice; 3) while
synthetic PPARa agonists are known to stimulate plasma TG
clearance [21], no evidence is available that points to differences in
plasma TG clearance and tissue fatty acid uptake between WT
and PPARa 2/2 mice; 4) genes that are upregulated by fatty
acids in a PPARa-independent manner were induced to the same
extent in WT and PPARa 2/2 mice (data not shown), suggesting
that the dietary fatty acids were taken up at the same rate in liver
of WT and PPARa 2/2 mice.
While PPARa activity is known to respond to changes in dietary
fat content and composition [22–24], the large dominance of
PPARa in fatty acid-dependent gene regulation in liver is
surprising given that the activity of numerous transcription factors
can be modulated by fatty acids, including SREBP-1, HNF4a,
LXRs, FXR, RXRs, NF-kB, as well as PPARb/d and PPARc
[25–37]. For several of these proteins, including RXRs and
HNF4a, physical binding by fatty acids or fatty acyl-CoAs has
Figure 5. Close agreement between fatty acid-dependent gene
regulation in vivo and in vitro. mRNA expression of three genes
(Pdk4, Ehhadh and Cyp4A14) was determined in mouse liver and in rat
hepatoma FAO cells using quantitative real-time PCR. Results are shown
as fold-change compared to control group. Error bars represent SD.
doi:10.1371/journal.pone.0001681.g005
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been demonstrated [30–32,38–42]. RXR forms a permissive
heterodimer with PPARa and accordingly it may be theorized that
transcriptional activation of PPAR target genes by fatty acids may
occur via their binding to either the PPARa and/or RXR moiety.
The loss of fatty acid-dependent gene regulation in PPARa 2/2
mice, the very large overlap in gene regulation between unsaturated
fatty acids andWY14643, and the less potent binding of fatty acids to
RXR relative to PPARa strongly suggest a dominant role for PPARa
in gene regulation by unsaturated fatty acids [28,31,43,44].
However, an additional role for RXR is hard to exclude as the
effects of RXR activation seem to occur primarily via PPARa [45]. It
remains to be investigated to what extent the dominant role of
PPARa in gene regulation by unsaturated fatty acids extends to
tissues other than liver. Likely, the relative role of other transcription
factors is related to their relative expression in a particular tissue.
Although it is clear that gene regulation by unsaturated fatty
acids is highly dependent on PPARa, genes that are regulated in a
PPARa-dependent manner do not necessarily represent direct
PPARa targets. Some regulation is also expected to occur
indirectly via activation of other transcription factors that are
under direct control of PPARa. Analysis of the microarray data
showed very little changes in the expression of other nuclear
receptors in response to the intervention with the exception of
CAR, which was upregulated, and RXRa and AhR, which were
downregulated, although not necessarily in all treatments. The
nuclear receptor CAR was recently identified as a PPARa target
[46], suggesting that some genes may be regulated by PPARa and
fatty acids via CAR. Secondary gene regulation was likely kept to a
minimum by harvesting the livers only six hours after the oral
gavage. It should also be noted that none of the putative fatty acid
responsive transcription factors were significantly decreased in
PPARa 2/2 mice, suggesting that their transcriptional regulatory
function is not intrinsically suppressed in PPARa 2/2 mice.
Our study shows a clear hierarchy between unsaturated dietary
fatty acids in terms of number of significantly changed genes and
fold-induction of genes, with especially C22:6 behaving as a highly
potent inducer of PPARa-dependent gene expression. The
difference in in vivo PPARa-activating potency between the dietary
fatty acids was reproduced in vitro and thus suggest an intrinsic
difference in PPARa-activating potency between dietary unsatu-
rated fatty acids, which is supported by in vitro receptor binding
and transactivation studies and thus likely reflects differences in
binding affinity for PPARa [19,25–29]. Even though C18:2 was
not the most potent inducer of gene expression, one could
speculate that it likely represents the quantitatively most important
dietary activator of PPARa, as the average intake of C18:2 is much
higher than that of C18:3, C20:5 and C22:6.
In recent years, the concept of Selective PPAR Modulators
(SPPARM) has emerged by analogy to Selective Estrogen Receptor
Modulators (SERM). According to this concept, different PPAR
agonists would induce differential gene expression based on selective
receptor-coregulator interactions. While recent evidence supports
the concept of selective PPARc modulation [47–49], only limited
data are available on PPARa [50]. The design of our study allowed
us to explore the concept of SPPARM in the comparison between
unsaturated fatty acids and synthetic agonists. We hypothesized that
fatty acids and synthetic PPARa agonists, while both activating
PPARa, may induce differential gene expression patterns possibly
via selective receptor-coregulator interactions.
In our analysis we found that almost every gene significantly up-
or downregulated by C22:6 was also significantly up- or downreg-
ulated by WY14643, respectively. Clearly, the reverse was not true,
illustrating that WY14643 is a more potent PPARa agonist than
C22:6. Importantly, the scatter plot indicated that across all
probesets the relative induction of gene expression by C22:6 when
related toWY14643 was remarkably constant, suggesting that C22:6
behaves as a less potent, yet almost equally specific PPARa agonist.
Nevertheless, several genes could be identified that were upregulated
disproportionally strongly byWY14643 including Cd36, Fabp4 (aP2),
and Cpt1b, or by C22:6 including Prlr and Txnip (Figure 3B). Thus,
differences in gene regulation between C22:6 and WY14643 could
not entirely be accounted for by the lesser potency of C22:6.
Interestingly, using the Nuclear Receptor PamChipH assay, at least 4
interactions, representing the coregulator proteins TRIP3, TRIP8,
RIP140, and the nuclear receptor SHP1, seemed to be stimulated
specifically by WY14643. However, no PPARa-coregulator inter-
actions could be identified that were stimulated specifically by C22:6
and not WY14643.
Figure 6. Cofactor recruitment assay with WY14643 and C22:6. The Nuclear Receptor PamChipH assay was used to measure the interaction
between PPARa and immobilized peptides corresponding to specific coregulator-nuclear receptor binding regions. Measurements were performed in
the presence of control (EtOH), WY14643 (5 mM) or C22:6 (100 mM). Arrows point to those co-activators selectively recruited by WY14643 but not
C22:6. All images were taken after 100 msec exposure time.
doi:10.1371/journal.pone.0001681.g006
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Overall, similar observations were made for the other fatty acids
studied, although compared to C22:6 they were less potent and/or
less specific activators of PPARa, especially C18:1. The data
indicate that in general dietary PUFAs mimic the effect of
WY14643 on hepatic gene expression in terms of regulation of
target genes and molecular mechanism, including coregulator
interactions. In addition to being a more potent PPARa agonist in
comparison with unsaturated fatty acids, WY14643 dyspropor-
tionally induces expression of specific genes, which may be
mediated via interactions with specific coactivator proteins
including RIP140. Thus, our data underscore the concept of
selective PPARa modulation when comparing WY14643 with
endogenous PPARa agonists, e.g. PUFAs.
Currently, one major drawback when performing microarray
analyses on data derived from dietary intervention studies is the
lack of proper statistical tools. The statistical methods developed to
cope with the huge amount of data derived from microarray
analyses work sufficiently well for stronger interventions, such as
drug studies. When dealing with nutrition, however, changes in
gene expression are often weak although no less important.
Multiple testing methods normally used in microarray analyses to
correct for false positives include FDR (false discovery rate) and Q-
value [51–53]. These methods are usually too restrictive for
nutritional intervention, however, and will result in a loss of
important results, as became apparent in the present study. Use of
Q-value instead of P-value resulted in loss of a considerable
amount of important information (data not shown). Numerous
quantitative real-time PCR reactions have been carried out on the
livers from this study supporting the use of the P-value.
In conclusion, dietary unsaturated fatty acids, especially
docosahexaenoic acid and other PUFAs, acutely influence gene
expression in mouse liver which, despite the presence of numerous
other putative fatty acid-dependent transcription factors, is almost
entirely mediated by PPARa. Consequently, dietary PUFAs
largely mimic the effect of synthetic PPARa agonists on hepatic
gene expression, both in terms of regulation of specific target genes
and molecular mechanism including coregulator interactions,
although compared to WY14643 and fenofibrate they are clearly
less potent PPARa agonists. Our analysis underscores the power of
a (nutri)genomics approach to investigate the potential molecular
mechanisms underlying the effect of specific dietary components
on (biomarkers of) health.
Materials and Methods
Materials
WY14643 was purchased from ChemSyn Laboratories (Lenexa,
KS, USA). Triolein was from Fluka (Zwijndrecht, The Nether-
lands). Trilinolein, trilinolenin, tridocosahexaenoin and trieicosa-
pentaenoin were from Nu-Chek-Prep, Inc. (Elysian, MN, USA).
Fetal bovine serum and penicillin/streptomycin were from
Cambrex Bioscience (Seraing, Belgium). SYBR Green was
purchased from Eurogentec (Seraing, Belgium). All other chem-
icals were from Sigma (Zwijndrecht, The Netherlands).
Animals
Male pure-bred SV129 and PPARa 2/2 mice (2–6 months of
age) on a SV129 background were used. Two weeks before start of
the experiment, the animals were switched to a run-in diet
consisting of a modified AIN76A diet (corn oil was replaced by
olive oil) (Research Diet Services, Wijk bij Duurstede, The
Netherlands). Starting at 5 a.m. the animals were fasted for
4 hours followed by an intragastric gavage of 400 ml synthetic
triglyceride (triolein, trilinolein, trilinolenin, trieicosapentaenoin or
tridocosahexaenoin) (Figure 1). WY14643 and fenofibrate were
given as 10 mg/ml suspension in 0.5% carboxymethyl cellulose,
which also served as control treatment (400 ml). Four to five mice
per group were used, adding up to 78 mice in total. 6 hours after
gavage, mice were anaesthetized with a mixture of isofluorane
(1.5%), nitrous oxide (70%) and oxygen (30%). Blood was collected
by orbital puncture, after which the mice were sacrificed by
cervical dislocation. Livers were removed, snap-frozen in liquid
nitrogen and stored at 280uC until further analysis. For RNA
analyses, tissue from the same part of the liver lobe was used.
The animal studies were approved by the Local Committee for
Care and Use of Laboratory Animals at Wageningen University.
Lipid absorption and tissue distribution
Measurement of intestinal lipid absorption was carried out
exactly as previously described [54]. For the lipid loading test WT
mice were fasted for 4 hours followed by administration of 400 ml
olive oil via intragastric gavage. Blood was collected by tail
bleeding every 2 hours for plasma TG measurement. Tissue
uptake of [3H]-labeled TG packaged into VLDL-like emulsion
particles was measured as previously described [55]. The data
shown reflect percentage of bolus radioactivity taken up after
30 minutes by a specific tissue expressed per gram tissue.
Triglycerides
Plasma and liver triglycerides were measured with a commer-
cially available kit from Instruchemie (Delfzijl, The Netherlands).
Livers were weighed and homogenized in a buffer (pH 7.5)
containing 250 mM sucrose, 1 mM EDTA and 10 mM Tris, with
a final tissue concentration of 5%. 2 ml of plasma or liver
homogenate was used to determine TG.
RNA isolation and qRT-PCR
Total liver RNA was isolated with TRIzol reagent (Invitrogen,
Breda, The Netherlands) according to manufacturer’s instructions.
A NanoDrop ND-1000 spectrophotometer (Isogen, Maarssen,
The Netherlands) was used to determine RNA concentrations.
1 mg of total RNA was reverse transcribed using iScript (Bio-Rad,
Veenendaal, The Netherlands). cDNA was amplified on a Bio-
Rad MyIQ or iCycler PCR machine using Platinum Taq DNA
polymerase (Invitrogen, Breda, The Netherlands). PCR primer
sequences were taken from the PrimerBank [56] and ordered from
Eurogentec (Seraing, Belgium). Sequences of the primers used are
available upon request.
Affymetrix microarray
Total RNA from mouse liver was extracted with TRIzol
reagent, and purified and DNAse treated using the SV Total RNA
Isolation System (Promega, Leiden, The Netherlands). RNA
quality was assessed on an Agilent 2100 bioanalyzer (Agilent
Technologies, Amsterdam, the Netherlands) with 6000 Nano
Chips using the Eukaryote Total RNA Nano assay. RNA was
judged as suitable for array hybridization only if samples showed
intact bands corresponding to the 18S and 28S rRNA subunits,
displayed no chromosomal peaks or RNA degradation products,
and had a RIN (RNA integrity number) above 8.0. Five
micrograms of RNA were used for one cycle cRNA synthesis
(Affymetrix, Santa Clara, CA). Hybridization, washing and
scanning of Affymetrix Mouse Genome 430 2.0 arrays was carried
out according to standard Affymetrix protocols.
Packages from the Bioconductor project were used for analyzing
the scanned Affymetrix arrays [57]. Arrays were normalized using
quartile normalization, and expression estimates were compiled
using GC-RMA applying the empirical Bayes approach [58]. A
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non-specific filtering step was applied to remove probesets with
low variation, as they provide no discriminating power [59]. Only
those probesets were included that had an inter-quartile range
(IQR) across the samples of at least 0.25 on the log2-scale.
Differentially expressed probesets were identified using linear
models, applying moderated t-statistics that implement empirical
Bayes regularization of standard errors [9].
Comparisons were made between wild-type treated and
untreated (control) and also between PPARa 2/2 treated and
untreated animals. Probesets that presented a P-value ,0.01 were
considered to be significantly changed by treatment. If a probeset
was significantly changed in the wild-type but not the PPARa 2/
2 mouse, it was considered to be PPARa-dependent (also
probesets that were significantly changed in the PPARa 2/2
mouse, but had a fold-change ,1.5 of the fold-change in the wild-
type mouse were included in this category).
Functional analysis of the array data was performed by a method
based on overrepresentation of Gene Ontology (GO) terms, where
the functional class score (FCS) method was used [60–62].
Cell culture
Rat hepatoma FAO cells were grown in DMEM containing
10% (vol/vol) fetal bovine serum, 100 U/ml penicillin and
100 mg/ml streptomycin. Cells were incubated with albumin-
bound fatty acids (100 mM) dissolved in ethanol or synthetic
PPARa ligands dissolved in DMSO (5 mM WY14643, 50 mM
fenofibrate). Incubation continued for 24 hours and was followed
by RNA isolation and qRT-PCR.
Cofactor recruitment assay
Nuclear Receptor PamChipH Arrays (PamGene, s’Hertogen-
bosch, The Netherlands) were used according to the manufacturer’s
instructions. Upon binding a ligand, PPARa undergoes a confor-
mational change which promotes the formation of a cofactor binding
pocket, subsequently allowing interaction with the so-called LxxLL
motif within some coregulators. The PamChipH arrays consist of 48
peptides encompassing the LxxLL motifs of 19 different coregulator
proteins ([63], Koppen et al. 2007. Micro Array assay for Real-time
analysis of Coregulator-Nuclear receptor Interaction. Manuscript
submitted.) Briefly, the arrays were incubated with glutathione-S-
transferase (GST)-tagged PPARa-LBD (Invitrogen, Breda, The
Netherlands) in the presence and absence of ligand. Quantification
of interaction between PPARa and coregulators was made using
Alexa488-conjugated anti-GST rabbit polyclonal antibody (Invitro-
gen). As ligands, either a negative control (EtOH), the synthetic
PPARa agonist WY14643 or one of the fatty acids C18:1, C18:2,
C18:3, C20:5 or C22:6 were used.
Supporting Information
Figure S1 Metabolic processing of dietary triglycerides. (A) WT
mice were given an oral fat load of 400 ml olive oil via intragastric
gavage. TG levels were measured in plasma collected via the tail
vein at the indicated time points. Errors bars represent SEM
(n=11). (B) Plasma TG of WT and PPARa 2/2 mice sacrificed
6 hours after intragastric gavage with synthetic triglycerides,
WY14643, or fenofibrate. Error bars represent SD (n= 4–5 per
group). (C) Intestinal triglyceride absorption rate was determined
in 5h fasted WT and PPARa 2/2 mice by measuring the
appearance of [3H] in plasma after intragastric gavage with 7uCi
glycerol-tri[3H]oleate mixed with olive oil (200 ml). Immediately
before the gavage, mice received an intraorbital injection of
tyloxapol (Triton WR1339) dissolved in saline at 500 mg/kg
bodyweight. Blood was sampled via the tail vein at the indicated
time points for measurement of 3H-activity. Error bars represent
SEM. (D) Liver TG of WT and PPARa 2/2 mice sacrificed
6 hours after intragastric gavage with synthetic triglycerides,
WY14643, or fenofibrate. Error bars represent SD (n= 4–5 per
group). (D) Tissue uptake of radiolabeled VLDL-like emulsion
particles. VLDL-like particles labeled with glycerol tri[3H]oleate
were injected into anesthetized mice. After 30 minutes, mice were
euthanized and tissues collected for measurement of 3H-activity.
Error bars represent SEM (n= 4).
Found at: doi:10.1371/journal.pone.0001681.s001 (1.62 MB TIF)
Figure S2 Close agreement between microarray and quantita-
tive real-time PCR data. mRNA expression of several genes was
measured by quantitative real-time PCR to confirm the results
from microarray. Results are shown as fold-change compared to
wild-type control. Error bars represent SD.
Found at: doi:10.1371/journal.pone.0001681.s002 (2.12 MB TIF)
Figure S3 Differential induction of genes involved in lipid
metabolism between dietary unsaturated fatty acids. For each
probeset, the induction of expression by each fatty acid was
expressed as a percentage relative to C22:6 (100%), using the
mean signal from 4–5 biological replicates. Each dot represents
one probeset. The horizontal bars represent the median
percentage of induction relative to C22:6 calculated separately
for each pathway and fatty acid. Only probesets showing
significant (P,0.01) upregulation by WY14643 were included in
the analysis. A list of probesets belonging to the three functional
classes can be found at http://nutrigene.4t.com/microarray/
ppar2007.
Found at: doi:10.1371/journal.pone.0001681.s003 (0.81 MB TIF)
Table S1 Total number as well as PPARa dependent up- and
downregulated probesets and corresponding genes for each
treatment group (P,0.01).
Found at: doi:10.1371/journal.pone.0001681.s004 (0.07 MB
DOC)
Table S2 Overlap in gene regulation between dietary unsatu-
rated fatty acids and WY14643. Genes were considered
statistically significantly regulated if P,0.01.
Found at: doi:10.1371/journal.pone.0001681.s005 (0.04 MB
DOC)
Table S3 Overrepresented GO classes in each treatment group
based on analysis with Functional Class Score method,
FDR,0.0001.
Found at: doi:10.1371/journal.pone.0001681.s006 (0.39 MB
DOC)
Table S4 Overlap in overrepresented Gene Ontology classes
between dietary unsaturated fatty acids and fenofibrate and
WY14643 based on analysis with Functional Class Score method,
FDR,0.0001.
Found at: doi:10.1371/journal.pone.0001681.s007 (0.04 MB
DOC)
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